Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Vaxart, Inc. (VXRT)

1.28   -0.02 (-1.54%) 11-25 13:00
Open: 1.31 Pre. Close: 1.3
High: 1.31 Low: 1.27
Volume: 974,806 Market Cap: 168(M)

Technical analysis

as of: 2022-11-25 2:01:24 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.87     One year: 2.12
Support: Support1: 1.25    Support2: 1.04
Resistance: Resistance1: 1.6    Resistance2: 1.82
Pivot: 1.42
Moving Average: MA(5): 1.32     MA(20): 1.47
MA(100): 2.72     MA(250): 3.88
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 11.3     %D(3): 15
RSI: RSI(14): 33.8
52-week: High: 7.61  Low: 1.25
Average Vol(K): 3-Month: 3,103 (K)  10-Days: 2,672 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VXRT ] has closed above bottom band by 18.8%. Bollinger Bands are 49.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.38 - 1.39 1.39 - 1.4
Low: 1.28 - 1.29 1.29 - 1.3
Close: 1.28 - 1.3 1.3 - 1.31

Company Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Headline News

Fri, 25 Nov 2022
Premarket Mover: Vaxart Inc (VXRT) Up 3.08% - InvestorsObserver

Wed, 09 Nov 2022
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace

Tue, 08 Nov 2022
Vaxart Earnings Beat, Revenue Misses In Q3 By -

Mon, 07 Nov 2022
Will Vaxart Inc (VXRT) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Tue, 01 Nov 2022
VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq

Fri, 09 Sep 2022
Vaxart Stock: Market Still Isn't Buying Oral Vaccine Thesis (NASDAQ:VXRT) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 131 (M)
% Held by Insiders 1.3032e+008 (%)
% Held by Institutions 0.8 (%)
Shares Short 25,510 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -9.955e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -65
Return on Assets (ttm) 823.2
Return on Equity (ttm) -31.5
Qtrly Rev. Growth 159000
Gross Profit (p.s.) 0
Sales Per Share -80.93
EBITDA (p.s.) -6.05823e+007
Qtrly Earnings Growth -0.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -81 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 1.06

Stock Dividends

Dividend 0
Forward Dividend 2.403e+007
Dividend Yield 0%
Dividend Pay Date 2022-12-19
Ex-Dividend Date 2012-11-08
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.